Lyell Immunopharma, Inc. Insider Trading

LYEL

Last 12 months

Insiders sold 608K and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. President and CEO Lynn Seely sold 149K on Aug 21, 13% of their stake, outside a plan. The last open-market buy by an executive or director was in Mar 2025.

Net open-market

−608K

0 buys · 26 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 6

executives and directors

Last open-market buy

Mar 2025

Mar 31, 2025

Get an email when LYEL's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 12	Jarrad Mattieu Aguirre Chief Medical Officer	SoldNo plan	422	$8.63	4K	2.1%	Form 4
Sep 10	David Shook Chief Medical Officer	SoldNo plan	500	$12.70	6K	2.4%	Form 4
Aug 21	Gary K. Lee Chief Scientific Officer	SoldNo plan	1,457	$15.54	23K	8.2%	Form 4
Aug 21	Stephen J. Hill Chief Operating Officer	SoldNo plan	989	$15.54	15K	5.6%	Form 4
Aug 21	Lynn Seely President and CEO	SoldNo plan	9,589	$15.54	149K	13%	Form 4
Aug 10	Veronica Sanchez Bulis VP, Corporate Controller	SoldNo plan	621	$14.34	9K	4.0%	Form 4
Aug 10	Gary K. Lee Chief Scientific Officer	SoldNo plan	131	$14.34	2K	0.7%	Form 4
Aug 10	Stephen J. Hill Chief Operating Officer	SoldNo plan	89	$14.34	1K	0.5%	Form 4
Aug 10	Lynn Seely President and CEO	SoldNo plan	390	$14.34	6K	0.5%	Form 4
Jul 17	Innovative Cellular Therapeutics Holdings Ltd Large holder	Sold10b5-1 plan	10	$13.70	$137	<0.1%	Form 4
Jul 16	Innovative Cellular Therapeutics Holdings Ltd Large holder	Sold10b5-1 plan	10	$13.73	$137	<0.1%	Form 4
Jun 10	David Shook Chief Medical Officer	SoldNo plan	1,977	$12.64	25K	8.6%	Form 4
May 11	Veronica Sanchez Bulis VP, Corporate Controller	SoldNo plan	217	$18.91	4K	1.4%	Form 4
May 11	Gary K. Lee Chief Scientific Officer	SoldNo plan	130	$18.92	2K	0.7%	Form 4
May 11	Stephen J. Hill Chief Operating Officer	SoldNo plan	89	$18.92	2K	0.5%	Form 4
May 11	Lynn Seely President and CEO	SoldNo plan	388	$18.91	7K	0.5%	Form 4
Mar 6	Arch Venture Partners IX Overage, L.p. Large holder	Bought	488,090	$25.61	$12.5M	52%	Form 4
Mar 6	Paul L Berns Large holder	Bought	488,090	$25.61	$12.5M	52%	Form 4
Feb 11	Gary K. Lee Chief Scientific Officer	SoldNo plan	1,671	$23.39	39K	9.0%	Form 4
Feb 11	Stephen J. Hill Chief Operating Officer	SoldNo plan	1,236	$23.39	29K	6.5%	Form 4
Feb 11	Lynn Seely President and CEO	SoldNo plan	7,455	$23.39	174K	9.1%	Form 4
Feb 10	Veronica Sanchez Bulis VP, Corporate Controller	SoldNo plan	254	$23.12	6K	1.6%	Form 4
Feb 10	Gary K. Lee Chief Scientific Officer	SoldNo plan	147	$23.12	3K	0.8%	Form 4
Feb 10	Stephen J. Hill Chief Operating Officer	SoldNo plan	109	$23.12	3K	0.6%	Form 4
Feb 10	Lynn Seely President and CEO	SoldNo plan	438	$23.12	10K	0.5%	Form 4
Dec 24, 2025 – Dec 30, 2025	Veronica Sanchez Bulis VP, Corporate Controller	SoldNo plan 2 parts	2,072	$35.80 average	74K	22%	Form 4
Nov 10, 2025	Veronica Sanchez Bulis VP, Corporate Controller	SoldNo plan	239	$16.10	4K	2.5%	Form 4
Nov 10, 2025	Gary K. Lee Chief Scientific Officer	SoldNo plan	138	$16.16	2K	0.9%	Form 4
Nov 10, 2025	Stephen J. Hill Chief Operating Officer	SoldNo plan	95	$16.12	2K	0.6%	Form 4
Nov 10, 2025	Lynn Seely President and CEO	SoldNo plan	412	$16.11	7K	0.6%	Form 4
Aug 21, 2025	Lynn Seely President and CEO	SoldNo plan	7,257	$10.54	76K	9.7%	Form 4
Aug 21, 2025	Stephen J. Hill Chief Operating Officer	SoldNo plan	1,004	$10.54	11K	6.0%	Form 4
Aug 21, 2025	Charles W. Newton Chief Financial Officer	SoldNo plan	1,453	$10.54	15K	5.4%	Form 4
Aug 21, 2025	Gary K. Lee Chief Scientific Officer	SoldNo plan	1,453	$10.54	15K	8.6%	Form 4
Aug 11, 2025 – Aug 12, 2025	Lynn Seely President and CEO	SoldNo plan 2 parts	797	$10.43 average	8K	2.2%	Form 4
Aug 11, 2025 – Aug 12, 2025	Stephen J. Hill Chief Operating Officer	SoldNo plan 2 parts	185	$10.43 average	2K	2.0%	Form 4
Aug 11, 2025 – Aug 12, 2025	Gary K. Lee Chief Scientific Officer	SoldNo plan 2 parts	267	$10.43 average	3K	2.9%	Form 4
Aug 11, 2025 – Aug 12, 2025	Charles W. Newton Chief Financial Officer	SoldNo plan 2 parts	267	$10.43 average	3K	1.4%	Form 4
Mar 31, 2025	Otis W Brawley Director	Bought	35,640	$0.56	20K	New	Form 4
Mar 21, 2025	Sumant Ramachandra Director	Bought	200,000	$0.58	116K	New	Form 4

Oct 12No plan
Jarrad Mattieu Aguirre
Chief Medical Officer · sold 422 at $8.63
4K
2.1% of stake
Sep 10No plan
David Shook
Chief Medical Officer · sold 500 at $12.70
6K
2.4% of stake
Aug 21No plan
Gary K. Lee
Chief Scientific Officer · sold 1,457 at $15.54
23K
8.2% of stake
Aug 21No plan
Stephen J. Hill
Chief Operating Officer · sold 989 at $15.54
15K
5.6% of stake
Aug 21No plan
Lynn Seely
President and CEO · sold 9,589 at $15.54
149K
13% of stake
Aug 10No plan
Veronica Sanchez Bulis
VP, Corporate Controller · sold 621 at $14.34
9K
4.0% of stake
Aug 10No plan
Gary K. Lee
Chief Scientific Officer · sold 131 at $14.34
2K
0.7% of stake
Aug 10No plan
Stephen J. Hill
Chief Operating Officer · sold 89 at $14.34
1K
0.5% of stake
Aug 10No plan
Lynn Seely
President and CEO · sold 390 at $14.34
6K
0.5% of stake
Jul 1710b5-1 plan
Innovative Cellular Therapeutics Holdings Ltd
Large holder · sold 10 at $13.70
$137
<0.1% of stake
Jul 1610b5-1 plan
Innovative Cellular Therapeutics Holdings Ltd
Large holder · sold 10 at $13.73
$137
<0.1% of stake
Jun 10No plan
David Shook
Chief Medical Officer · sold 1,977 at $12.64
25K
8.6% of stake
May 11No plan
Veronica Sanchez Bulis
VP, Corporate Controller · sold 217 at $18.91
4K
1.4% of stake
May 11No plan
Gary K. Lee
Chief Scientific Officer · sold 130 at $18.92
2K
0.7% of stake
May 11No plan
Stephen J. Hill
Chief Operating Officer · sold 89 at $18.92
2K
0.5% of stake
May 11No plan
Lynn Seely
President and CEO · sold 388 at $18.91
7K
0.5% of stake
Mar 6
Arch Venture Partners IX Overage, L.p.
Large holder · bought 488,090 at $25.61
$12.5M
52% of stake
Mar 6
Paul L Berns
Large holder · bought 488,090 at $25.61
$12.5M
52% of stake
Feb 11No plan
Gary K. Lee
Chief Scientific Officer · sold 1,671 at $23.39
39K
9.0% of stake
Feb 11No plan
Stephen J. Hill
Chief Operating Officer · sold 1,236 at $23.39
29K
6.5% of stake
Feb 11No plan
Lynn Seely
President and CEO · sold 7,455 at $23.39
174K
9.1% of stake
Feb 10No plan
Veronica Sanchez Bulis
VP, Corporate Controller · sold 254 at $23.12
6K
1.6% of stake
Feb 10No plan
Gary K. Lee
Chief Scientific Officer · sold 147 at $23.12
3K
0.8% of stake
Feb 10No plan
Stephen J. Hill
Chief Operating Officer · sold 109 at $23.12
3K
0.6% of stake
Feb 10No plan
Lynn Seely
President and CEO · sold 438 at $23.12
10K
0.5% of stake
Dec 24, 2025 – Dec 30, 2025No plan
Veronica Sanchez Bulis
VP, Corporate Controller · sold 2,072 at avg $35.80
74K
22% of stake
Nov 10, 2025No plan
Veronica Sanchez Bulis
VP, Corporate Controller · sold 239 at $16.10
4K
2.5% of stake
Nov 10, 2025No plan
Gary K. Lee
Chief Scientific Officer · sold 138 at $16.16
2K
0.9% of stake
Nov 10, 2025No plan
Stephen J. Hill
Chief Operating Officer · sold 95 at $16.12
2K
0.6% of stake
Nov 10, 2025No plan
Lynn Seely
President and CEO · sold 412 at $16.11
7K
0.6% of stake
Aug 21, 2025No plan
Lynn Seely
President and CEO · sold 7,257 at $10.54
76K
9.7% of stake
Aug 21, 2025No plan
Stephen J. Hill
Chief Operating Officer · sold 1,004 at $10.54
11K
6.0% of stake
Aug 21, 2025No plan
Charles W. Newton
Chief Financial Officer · sold 1,453 at $10.54
15K
5.4% of stake
Aug 21, 2025No plan
Gary K. Lee
Chief Scientific Officer · sold 1,453 at $10.54
15K
8.6% of stake
Aug 11, 2025 – Aug 12, 2025No plan
Lynn Seely
President and CEO · sold 797 at avg $10.43
8K
2.2% of stake
Aug 11, 2025 – Aug 12, 2025No plan
Stephen J. Hill
Chief Operating Officer · sold 185 at avg $10.43
2K
2.0% of stake
Aug 11, 2025 – Aug 12, 2025No plan
Gary K. Lee
Chief Scientific Officer · sold 267 at avg $10.43
3K
2.9% of stake
Aug 11, 2025 – Aug 12, 2025No plan
Charles W. Newton
Chief Financial Officer · sold 267 at avg $10.43
3K
1.4% of stake
Mar 31, 2025
Otis W Brawley
Director · bought 35,640 at $0.56
20K
New position
Mar 21, 2025
Sumant Ramachandra
Director · bought 200,000 at $0.58
116K
New position

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch LYEL, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with LYEL

CompareIntrinsic value

BDPTBioadaptives Inc.

$0.00-5.88%25

IBOImpact Biomedical Inc.

$4.10+1.99%20

JUNSJupiter Neurosciences Inc.

$2.46+1.23%10

SKVISkinvisible Inc.

$0.16+0.00%0

ADTXAditxt Inc.

$0.00+33.33%20

NTHINeonC Technologies Holdings

$3.17+3.26%10

ALTAltimmune, Inc.

$2.12+3.92%10

GNLXGenelux Corp.

$1.96+2.08%10

Held by ETFs

LYEL is in 5 US ETFs. The largest of them, with LYEL's weight in each:

Spot a number that looks wrong? Check it in LYEL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing LYEL

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.